Please assess the completion status of the following clinical trial:

Trial Title: Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who has been receiving dietary therapy and a stable dose and regimen of insulin over 8 weeks before at the time of an observation term start~* Patients whose HbA1c at the time of an observation term start is 7.5% or more and less than 10.0%~Exclusion Criteria:~* Type 1 Diabetes Mellitus~* Patients with serious diabetic complications and other serious complications

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- KAD-1229/KAD-1229 (Type: EXPERIMENTAL): Patients are administered KAD-1229 for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with insulin throughout the study.
- Placebo/KAD-1229 (Type: OTHER): Patients are administered Placebo for 16 weeks (double-blind period), followed by KAD-1229 for up to 52 weeks (open-label period) with Insulin throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).